1-20 of 43
Jan Dürig
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeted Treatment Additions Ibrutinib + Bortezomib + R-CHOP for Higher-Risk DLBCL: Efficacy, Feasibility and Molecular Signatures for Future Treatment Decisions

Sophy Denker, Aitomi Bittner, Julia Kase, Mareike Frick, Jörg Hoffmann, Corinna Trenker, Ulrich Keller, Christian Bogner, Andreas Hüttmann, Jan Dürig, Martin Janz, Stephan Mathas, Reinhard Marks, Ulrike Krohn, Il-Kang Na, Paulina Richter-Pechanska, Animesh Bhattacharya, Bernhard Gebauer, Lynn Savic, Norbert Hübner, Altuna Akalin, Roland Eils, Lars Bullinger, Clemens Schmitt
Journal: Blood
Blood (2024) 144 (Supplement 1): 6188.
https://doi.org/10.1182/blood-2024-207123
Published: 2024
Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Moritz Fürstenau, Matthias Ritgen, Sandra Robrecht, Julia Von Tresckow, Can Zhang, Anke Schilhabel, Michael Gregor, Patrick Thornton, Philipp Bernhard Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Neta Goldschmidt, Elisabeth Vandenberghe, Davide Rossi, Rudolf A. Benz, Daniel Heintel, Christian Bjørn Poulsen, Ilse Christiansen, Henrik Frederiksen, Lisbeth Enggaard, Eduardus Posthuma, Djamila Issa, Hein Visser, Mar Bellido, Nadine Kutsch, Jan Dürig, Alexander Stehle, Matthias C. Voehringer, Sebastian Böttcher, Clemens Schulte, Florian Simon, Anna-Maria Fink, Kirsten Fischer, Emily Holmes, Karl-Anton Kreuzer, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Michael Hallek, Arnon P. Kater, Carsten Utoft Niemann, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 635.
https://doi.org/10.1182/blood-2023-173709
Published: 2023
Journal Articles

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Gigi Nu Hoang Quy Ton, Katharina Kriegsmann, Mohamed H.S. Awwad, Axel Benner, Uta Bertsch, Britta Besemer, Mathias Hänel, Roland Fenk, Jana Schlenzka, Markus Munder, Jan Dürig, Igor Wolfgang Blau, Stefanie Huhn, Dirk Hose, Anna Jauch, Andreas Neubauer, Niels Weinhold, Christof Scheid, Roland Schroers, Ivana von Metzler, Aneta Schieferdecker, Jörg Thomalla, Peter Reimer, Rolf Mahlberg, Ullrich Graeven, Stephan Kremers, Uwe Martens, Christian Kunz, Manfred Hensel, Andrea Seidel-Glätzer, Katja Weisel, Hans Salwender, Carsten Müller-Tidow, Marc S. Raab, Hartmut Goldschmidt, Elias K. Mai, Michael Hundemer
Journal: Blood
Blood (2023) 142 (Supplement 1): 1991.
https://doi.org/10.1182/blood-2023-189169
Published: 2023
Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Clinical Trials & Observations
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Othman Al-Sawaf, Karl-Anton Kreuzer, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (11): 961–972.
https://doi.org/10.1182/blood.2023020013
Published: 2023
Includes: Supplemental data
Journal Articles

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia Von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Furstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 834–836.
https://doi.org/10.1182/blood-2022-163245
Published: 2022
Journal Articles

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Marie José Kersten, Martin Dreyling, Kim M. Linton, Dana Chitu, Sanne Tonino, Marcel Kap, Roberto D Liu, Martine E.D. Chamuleau, Hein P.J. Visser, Eva De Jongh, Erik WAF Marijt, Maria B.L. Leijs, Yavuz M. Bilgin, Jan Dürig, Pamela McKay, Tjeerd J.F. Snijders, Andrew Pettitt, Monique C. Minnema, Gabriele Prange-Krex, Maria Cuijpers, Lara H. Böhmer, Lidwine W. Tick, Axel Florschütz, Matthijs Silbermann, Rob Fijnheer, Aart Beeker, Nelleke Tolboom, Cristina Mitea, Anne IJ Arens, Gerben JC Zwezerijnen, Wolfram Klapper, Sarah E. Coupland, Daphne de Jong, Jeanette K. Doorduijn, Josée M. Zijlstra
Journal: Blood
Blood (2022) 140 (Supplement 1): 2283–2285.
https://doi.org/10.1182/blood-2022-156085
Published: 2022
Journal Articles

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Clinical Trials & Observations
Henriette Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang, Eugen Tausch, Christof Schneider, Johannes Bloehdorn, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna L. Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 139 (9): 1318–1329.
https://doi.org/10.1182/blood.2021013208
Published: 2022
Includes: Supplemental data
Journal Articles

Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network

Elias K Mai, Thomas Hielscher, Uta Bertsch, Hans Salwender, Sonja Zweegman, Markus Munder, Lucia Pantani, Peter Brossart, Meral Beksac, Igor Wolfgang Blau, Marc-Steffen Raab, Jan Dürig, Nicola Giesen, Britta Besemer, Roland Fenk, Peter Reimer, Bronno van der Holt, Mathias Haenel, Ivana v. Metzler, Ullrich Graeven, Mario Boccadoro, Christof Scheid, Meletios A. Dimopoulos, Katja Weisel, Michele Cavo, Pieter Sonneveld, Hartmut Goldschmidt
Journal: Blood
Blood (2021) 138 (Supplement 1): 3792.
https://doi.org/10.1182/blood-2021-145289
Published: 2021
Journal Articles

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Britta Besemer, Mathias Haenel, Kaya Miah, Roland Fenk, Jana Schlenzka, Markus Munder, Jan Dürig, Igor Wolfgang Blau, Stefanie Huhn, Dirk Hose, Anna Jauch, Christina Kunz, Andreas Neubauer, Christof Scheid, Roland Schroers, Ivana v. Metzler, Aneta Schieferdecker, Joerg Thomalla, Peter Reimer, Rolf Mahlberg, Ullrich Graeven, Stephan Kremers, Uwe M. Martens, Christian Kunz, Manfred Hensel, Andrea Seidel-Glaetzer, Katja Weisel, Marc-Steffen Raab, Hans Salwender
Journal: Blood
Blood (2021) 138 (Supplement 1): 486.
https://doi.org/10.1182/blood-2021-147323
Published: 2021
Journal Articles

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Hartmut Goldschmidt, Elias K Mai, Eva Nievergall, Roland Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana v. Metzler, Mathias Haenel, Christoph Mann, Anne-Marie Asemissen, Bernhard Heilmeier, Stefanie Huhn, Katharina Kriegsmann, Niels Weinhold, Steffen P. Luntz, Tobias A. W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Cyrus Khandanpour, Wolfgang Knauf, Markus Munder, Thomas Geer, Hendrik Riesenberg, Joerg Thomalla, Martin Hoffmann, Marc-Steffen Raab, Hans Salwender, Katja Weisel
Journal: Blood
Blood (2021) 138 (Supplement 1): 463.
https://doi.org/10.1182/blood-2021-145097
Published: 2021
Journal Articles

A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform

Mattia D'Agostino, MD, Juan-José Lahuerta, MD PhD, Ruth Wester, MD, Anders Waage, MD PhD, Uta Bertsch, Elena Zamagni, Maria-Victoria Mateos, MD PhD, Alessandra Larocca, Daniele Dall'Olio, Niels W. C. J. van de Donk, David Cairns, MSc, PhD, Serena Rocchi, Hans Salwender, MD, Joan Blade Creixenti, Bronno van der Holt, PhD, Castellani Gastone, Giovannino Ciccone, Andrea Capra, Jan Dürig, MD, Sara Bringhen, MD, Sonja Zweegman, MDPhD, Michele Cavo, Hartmut Goldschmidt, MD, Gordon Cook, MB ChB, PhD, Jesus Maria Hernández-Rivas, MD PhD, Jesus F. San-Miguel, MD PhD, Mario Boccadoro, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 34–37.
https://doi.org/10.1182/blood-2020-137021
Published: 2020
Journal Articles

Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Anna-Maria Fink, MD, Paula Cramer, Carmen D. Herling, MD PhD, Julia Von Tresckow, MD, Elisabeth Lange, MD, Sebastian Böttcher, MD PhD, Michael G. Kiehl, MD PhD, Martin Dreyling, MD, Ulrich Jaeger, Michael Gregor, MD, Ursula Vehling-Kaiser, MD, Matthias Ritgen, MD, Jan Dürig, MD, Eugen Tausch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Valentin Goede, MD, Michael Hallek, MD, Barbara Eichhorst, MD, Petra Langerbeins, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139242
Published: 2020
Journal Articles

The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Norbert Grząśko, MD PhD, Stefan Knop, Hartmut Goldschmidt, MD, Marc S Raab, MD PhD, Jan Dürig, Sara Bringhen, Mattia D'Agostino, MD, Barbara Gamberi, Elena Rivolti, MD, Angelo Vacca, MD PhD, Roberto Ria, MD, Artur Jurczyszyn, MD, Jorge Castellano Acosta, MD, Doris Lang, Guy Lemaillet, PhD, Bansod Sudhir, MD, Monika Szarejko, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1899.
https://doi.org/10.1182/blood-2019-129827
Published: 2019
Journal Articles

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, MD PhD, Christian Lerchenmüller, MD, Manfred Hensel, MD, Martin Goerner, MD, Christian Buske, MD PhD, Holger Schulz, Burkhard Schmidt, MD, Georgi Kojouharoff, MD, Elisabeth Lange, MD, Wolfgang Willenbacher, MD PhD, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, MD, Axel Hinke, PhD, Jasmin Wupperfeld, Richard Greil, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 343.
https://doi.org/10.1182/blood-2019-121909
Published: 2019
Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Meletios A. Dimopoulos, MD, Katja C. Weisel, MD, Philippe Moreau, MD, Larry D. Anderson, MD PhD, Darrell J White, MD, Jesús San-Miguel, Pieter Sonneveld, Monika Engelhardt, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Alessandro Corso, Jan Dürig, Michel Pavic, MD, Morten Salomo, MD PhD, Eva Casal, Ruiyun Jiang, Shankar Srinivasan, PhD MBA, Tuong Vi Nguyen, Tsvetan Biyukov, MD, Teresa Peluso, Paul G. Richardson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3120.
https://doi.org/10.1182/blood-2019-124349
Published: 2019
Journal Articles

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Christian Schmidt, MD, Anna-Katharina Zoellner, Vindi Jurinovic, Martin Sökler, MD, Roswitha Forstpointner, Sascha Haubner, MD, Christian Buske, MD, Andreas Viardot, MD, Ulrich Keller, Christiane Pott, Ullrich Graeven, MD, Reinhard Marks, Mathias Hänel, MD, Ruediger Liersch, Jan Dürig, Eva Hoster, Michael Unterhalt, Wolfgang Hiddemann
Journal: Blood
Blood (2018) 132 (Supplement 1): 448.
https://doi.org/10.1182/blood-2018-99-111692
Published: 2018
Journal Articles

Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

Anja Seckinger, Hans Jürgen Salwender, MD, Hans Martin, MD, Christof Scheid, Thomas Hielscher, Uta Bertsch, MD, Manuela Hummel, Anna Jauch, PhD, Wolfgang Knauf, Martina Emde, Susanne Beck, Kai Neben, Henk M. Lokhorst, MD PhD, Bronno van der Holt, PhD, Ulrich Duehrsen, MD, Jan Dürig, Hans-Walter Lindemann, MD, Ingo Schmidt-Wolf, Mathias Haenel, MD, Bernd Lathan, Marc S Raab, MD PhD, Carsten Müller-Tidow, MD, Pieter Sonneveld, MD PhD, Igor Wolfgang Blau, Jens Hillengass, MD, Katja Weisel, MD, Hartmut Goldschmidt, MD, Dirk Hose, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4485.
https://doi.org/10.1182/blood-2018-99-113284
Published: 2018
Journal Articles

MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Stefan Knop, Hartmut Goldschmidt, MD, Marc S Raab, MD PhD, Monika Szarejko, Artur Jurczyszyn, MD, Jan Dürig, Sara Bringhen, Barbara Gamberi, MD, Angelo Vacca, Jorge Castellano Acosta, MD, Guy Lemaillet, PhD, Cedric Cortijo, PhD, Bansod Sudhir, Norbert Grząśko, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1980.
https://doi.org/10.1182/blood-2018-99-112859
Published: 2018
Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

Meletios A Dimopoulos, MD, Katja Weisel, MD, Philippe Moreau, Larry Anderson, MD PhD, Darrell J White, MD, Jesus F San-Miguel, MD PhD, Pieter Sonneveld, MD PhD, Monika Engelhardt, MD, Matthew W Jenner, Alessandro Corso, MD, Jan Dürig, Michel Pavic, MD, Morten Salomo, Xin Yu, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Mohamed Zaki, MD PhD, Paul Richardson
Journal: Blood
Blood (2018) 132 (Supplement 1): 3278.
https://doi.org/10.1182/blood-2018-99-111869
Published: 2018
Journal Articles

Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus–infected individuals

Felicia A. Tucci, Simo Kitanovski, Patricia Johansson, Ludger Klein-Hitpass, Alisan Kahraman, Jan Dürig, Daniel Hoffmann, Ralf Küppers
Journal: Blood
Blood (2018) 131 (5): 546–557.
https://doi.org/10.1182/blood-2017-09-805762
Published: 2018
Includes: Supplemental data